Sarat Chandarlapaty

Jan 13, 2025 | nature.com | Dan Li |Li Yao |Fengshen Kuo |Jiaqian Luo |Alison Smith |Dong Gao | +7 more

AbstractMembers of the KMT2C/D–KDM6A complex are recurrently mutated in urothelial carcinoma and in histologically normal urothelium. Here, using genetically engineered mouse models, we demonstrate that Kmt2c/d knockout in the urothelium led to impaired differentiation, augmented responses to growth and inflammatory stimuli and sensitization to oncogenic transformation by carcinogen and oncogenes.

Oct 17, 2024 | nature.com | Nicholas Mai |Pedram Razavi |Anton Safonov |Chau Dang |Larry Norton |Mark E. Robson | +1 more

AbstractAfter disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results.

Aug 2, 2024 | nature.com | Antonio Marra |Sarat Chandarlapaty |Shanu Modi

Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-023-00849-9, published online 8 January 2024. In the version of the article initially published, there was an error in the second paragraph of the introduction, where “mouse erbB2” has been corrected to “human HER2” in the sentence now reading “Among these, a mouse mAb targeting human HER2 demonstrated remarkable preclinical activity…” in the HTML and PDF versions of article.

Jul 27, 2024 | nature.com | Nicholas Mai |Jie-Fu Chen |Sarat Chandarlapaty

AbstractSimultaneous presentation of two separate primary breast cancers of differing histology at initial diagnosis is an uncommon phenomenon; it is even rarer to find these pathologically distinct populations within the same biopsy.

Jan 25, 2024 | healio.com | Mark Leiser |Mindy Valcarcel |Adam Brufsky |Sarat Chandarlapaty

Perspective Back to Top Adam M. Brufsky, MD, PhD This is the decade of the ADC. Since the first report of an ADC in breast cancer in 2012, we now have three approved for treatment of metastatic breast cancer — ado-trastuzumab emtansine (Kadcyla, Genentech), often called T-DM1; fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) and sacituzumab govitecan (Trodelvy, Gilead) — as well as one of them, T-DM1, approved in the post-neoadjuvant early setting.